CSL stock: 52-week high puts recovery to the test

CSL's recovery is facing a fresh test after the shares reached a 52-week high, according to an analysis updated by The Bull on Friday, November 13, 2026. The analysis says the next phase depends less on momentum than on operational delivery across the business.

Plasma recovery leads the case

CSL's plasma operations remain the main recovery opportunity. Rising demand for immunoglobulin therapies, improved collection efficiency, manufacturing productivity and a better product mix are identified as potential drivers for CSL Behring.

The broader earnings picture remains mixed. CSL reported fiscal 2026 revenue of 15.8 billion US dollars, while impairment and restructuring charges contributed to a statutory loss of 2.6 billion US dollars. Underlying NPATA was 3.1 billion US dollars, giving investors a different view of operating performance.

Cost program carries more weight

The company delivered 176 million US dollars in pre-tax savings during fiscal 2026 and targets a further 220 million US dollars in fiscal 2027. The program is expected to reach annual pre-tax savings of 500 million to 550 million US dollars by fiscal 2028, making execution a central part of the investment case.

CSL Vifor faces generic competition in iron therapies, while CSL Seqirus is exposed to uneven demand in the US vaccine market. These pressures could limit how quickly cost reductions translate into sustainable organic growth.

CSL stock traded at 124.41 euros on Lang & Schwarz at 15:31 CET on Friday, November 13, 2026.

Australian equities are covered in Current market reports.

More news and analyses on CSL stock.